

B1  
CONT.  
produce single-stranded cDNA including the sequence of interest with the reverse transcriptase produced by the reverse transcriptase gene.

B2  
9. (Twice Amended) The method of claim [8] wherein the [transcript of the sequence of interest is linearized by a restriction endonuclease, the sequence of interest including an] inverted tandem repeat [comprising] comprises a restriction endonuclease site [in the single-stranded cDNA] when the sequence of interest is formed into a stem-loop intermediate by Watson-Crick base pairing of the inverted tandem repeat[, the restriction endonuclease] for cutting [the stem-loop intermediate at the] with a restriction endonuclease [site].

B3  
15. (Amended) The method of claim 9 [wherein the] additionally comprising transcribing a restriction endonuclease [transcribed] from [the] a restriction endonuclease gene in the nucleus of the cell that is specific for the restriction endonuclease site formed by Watson-Crick base pairing of the inverted tandem repeat.

#### REMARKS

In the Official Action of August 11, 2000, the restriction requirement was repeated and made final, the filing of the application with informal drawings was noted, and it was noted that Applicant overlooked requesting that the paper copy of the sequence listing included with Applicant's **Response to Official Action of March 16, 2000** replace the original sequence listing. Claims 8, 9, and 15 were rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to point out and claim that which Applicant regards as the invention. Finally, claims 7, 10, 11, 13, and 14 were indicated as being allowable over the prior art.

It is respectfully requested that the objection to the drawings be held in abeyance until the application is otherwise allowable. 37 C.F.R. 1.85(c), 1.111(b). Responsive to Applicant's inadvertent failure to request that the sequence listing submitted with Applicant's **Response to Official Action of March 16, 2000** replace the original sequence listing, Applicant hereby requests that the sequence listing submitted with that earlier **Response** be entered into the application in place of the original sequence listing.


Responsive to the §112 rejection, as set out above, Applicant canceled claim 8 to eliminate the reference to "linearizing" and amended claims 9 and 15. Reconsideration and withdrawal of that rejection is respectfully requested in light of these amendments.

Applicant appreciates the opportunity to interview the captioned application on October 18, 2000 and the amendments to claim 7 set out above are the amendments contemplated by the indication in the Interview Summary Record (Form PTO-413) that Applicant would be amending claim 7. Applicant submits the following additional comments regarding the subject matter discussed at that interview in accordance with the requirements of 37 C.F.R. 1.2 and 1.133.

Specifically, as indicated during the interview, Applicant filed an **Information Disclosure Statement** on the same day as the interview and then used the interview to review three references enclosed with that **Information Disclosure Statement**. Specifically, PCT applications Nos. PCT/US93/12029, PCT/US94/02169, and PCT/US95/07968 were reviewed during the interview. Attention is directed at this time to PCT application No. PCT/US93/06326, Mao, *et al.*, 85 Biochemistry 1777-1781 (1995), Mirochnitchenko, *et al.*, 269 J. Biol. Chem. 2380-2383 (1994), and Ohshima, *et al.*, 89 Proc. Natl. Acad. Sci. USA 1016-1020 (1992), all included with that **Information Disclosure Statement**. Applicant hesitates to call attention to these references because of the concern that, in calling attention to them, it will be inferred that Applicant does not consider the other references submitted with that **Information Disclosure Statement** to be important, or worse, that attention is being diverted from other references. Consequently, Applicant hereby also calls attention to 37 C.F.R. 1.97(h) indicating that an information disclosure statement is not to be construed as an admission that the information cited in the statement is considered material to patentability. By inference from §1.97(h), the fact that information cited in an information disclosure statement is not noted here should not be considered an indication that such information is not material to patentability.

Entry of the above amendments, the sequence listing submitted with Applicant's **Response to Official Action of March 16, 2000**, and all of the references submitted with Applicant's **Information Disclosure Statement** filed on October 18, 2000, reconsideration and withdrawal of the §112 rejection set out in the Official Action of August 11, 2000, allowance of the claims, and passage of the application to issuance are respectfully requested. In the event there are questions, it is respectfully requested that Applicant's counsel be contacted at the address and telephone number set out below.

Respectfully submitted,



Mark R. Wisner  
Registration No. 30,603  
Wisner & Associates  
2925 Briarpark, Suite 930  
Houston, TX 77042  
(713) 785-0555  
Fax: (713) 785-0561

ATTORNEY FOR APPLICANT

Date: February 12, 2001